1150617-52-9 Usage
Uses
Used in Pharmaceutical Research and Development:
5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine serves as a key intermediate in the synthesis of biologically active molecules. Its unique structure allows for the creation of new compounds with potential therapeutic properties, making it an essential component in drug discovery processes.
Used in the Synthesis of Anticancer Agents:
In the field of oncology, 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine is utilized as a precursor for developing novel anticancer drugs. Its ability to interact with and modify protein functions suggests that it may contribute to the design of molecules capable of targeting cancer cells more effectively.
Used in the Treatment of Neurological Disorders:
5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine has been studied for its potential role in the development of treatments for neurological disorders. Its influence on protein function could be harnessed to create molecules that address the underlying mechanisms of such conditions, offering new avenues for therapeutic intervention.
Used as a Reagent in Organic Synthesis:
Beyond its direct applications in medicine, 5-Bromo-4-methyl-1H-pyrrolo[2,3-b]pyridine also functions as a reagent in organic synthesis. It is employed in the creation of a variety of new drugs and bioactive molecules, contributing to the broader scope of chemical research and innovation in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1150617-52-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,0,6,1 and 7 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1150617-52:
(9*1)+(8*1)+(7*5)+(6*0)+(5*6)+(4*1)+(3*7)+(2*5)+(1*2)=119
119 % 10 = 9
So 1150617-52-9 is a valid CAS Registry Number.
1150617-52-9Relevant articles and documents
Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis
Klug, Dana M.,Mavrogiannaki, Eftychia M.,Forbes, Katherine C.,Silva, Lisseth,Diaz-Gonzalez, Rosario,Pérez-Moreno, Guiomar,Ceballos-Pérez, Gloria,Garcia-Hernández, Raquel,Bosch-Navarrete, Cristina,Cordón-Obras, Carlos,Gómez-Li?án, Claudia,Saura, Andreu,Momper, Jeremiah D.,Martinez-Martinez, Maria Santos,Manzano, Pilar,Syed, Ali,El-Sakkary, Nelly,Caffrey, Conor R.,Gamarro, Francisco,Ruiz-Perez, Luis Miguel,Gonzalez Pacanowska, Dolores,Ferrins, Lori,Navarro, Miguel,Pollastri, Michael P.
supporting information, p. 9404 - 9430 (2021/07/25)
Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.
IMIDAZOPYRIDIN-2-ONE DERIVATIVES
-
Page/Page column 32, (2011/04/24)
A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.
